France's Advicenne 2025 sales rise, net loss widens

Advicenne SA

26/03/2026 19:20

Overview

France specialty pharma's 2025 product sales rose 18.7%, led by Sibnayal growth in Europe

Company posted a wider net loss of €9.5 mln due to higher non-current charges

Outlook

Advicenne is working to extend its cash runway beyond Q2 2026 through financial restructuring

Result Drivers

SIBNAYAL SALES GROWTH - Co said European and Middle East sales of Sibnayal rose over 70%, driving overall product sales higher

R&D INVESTMENTS - Co said operating expenses were mainly allocated to R&D for U.S. FDA submission of ADV7103

Company press release: ID:nBw11MsH8a

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
FY EPS
-EUR 0.72
FY Net Income
-EUR 9.53 mln


Analyst Coverage

The one available analyst rating on the shares is "buy"

The average consensus recommendation for the pharmaceuticals peer group is "buy"

Wall Street's median 12-month price target for Advicenne SA is €4.00, about 105.3% above its March 26 closing price of €1.95

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)